About TearSolutions
TearSolutions is a company based in Charlottesville (United States) founded in 2013.. TearSolutions has raised $44.07 million across 12 funding rounds from investors including Santen Pharmaceuticals, VTC Innovation Fund and Pharmstandard. TearSolutions offers products and services including Lacripep. TearSolutions operates in a competitive market with competitors including Remegen, Oyster Point Pharmaceuticals, Biophytis, Azura Ophthalmics and Retrotope, among others.
- Headquarter Charlottesville, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$44.07 M (USD)
in 12 rounds
-
Latest Funding Round
$517 K (USD), Series B
Oct 29, 2025
-
Investors
Santen Pharmaceuticals
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TearSolutions
TearSolutions offers a comprehensive portfolio of products and services, including Lacripep. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Topical treatment to restore tear film and heal ocular surfaces.
Unlock access to complete
Unlock access to complete
Funding Insights of TearSolutions
TearSolutions has successfully raised a total of $44.07M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $517 thousand completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Series B — $517,000
-
First Round
First Round
(25 Jun 2014)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - TearSolutions | Valuation |
investors |
|
| Sep, 2024 | Amount | Series B - TearSolutions | Valuation |
investors |
|
| Sep, 2023 | Amount | Series B - TearSolutions | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TearSolutions
TearSolutions has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Santen Pharmaceuticals, VTC Innovation Fund and Pharmstandard. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
VC firm investing in seed & early stage companies in the US
|
Founded Year | Domain | Location | |
|
Early-stage VC firm funding companies in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TearSolutions
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TearSolutions
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tearsolutions Comparisons
Competitors of TearSolutions
TearSolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Remegen, Oyster Point Pharmaceuticals, Biophytis, Azura Ophthalmics and Retrotope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ophthalmological diseases are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for neuromuscular and age-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing therapies for meibomian gland dysfunction
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative and ophthalmological diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tearsolutions
Frequently Asked Questions about TearSolutions
When was TearSolutions founded?
TearSolutions was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is TearSolutions located?
TearSolutions is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Is TearSolutions a funded company?
TearSolutions is a funded company, having raised a total of $44.07M across 12 funding rounds to date. The company's 1st funding round was a Series B of $390K, raised on Jun 25, 2014.
What does TearSolutions do?
TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.
Who are the top competitors of TearSolutions?
TearSolutions's top competitors include Remegen, Lineage Cell Therapeutics and Oyster Point Pharmaceuticals.
What products or services does TearSolutions offer?
TearSolutions offers Lacripep.
Who are TearSolutions's investors?
TearSolutions has 5 investors. Key investors include Santen Pharmaceuticals, VTC Innovation Fund, Pharmstandard, LaunchCapital, and Center for Innovative Technology.